Menu Search
Equities

Frontage Holdings Corp

1521:HKG

Frontage Holdings Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.62
  • Today's Change0.01 / 1.64%
  • Shares traded11.22m
  • 1 Year change-69.46%
  • Beta1.3056
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Frontage Holdings Corp had net income fall -58.00% from 25.74m to 10.81m despite a 3.79% increase in revenues from 250.36m to 259.86m. An increase in the cost of goods sold as a percentage of sales from 64.37% to 69.83% was a component in the falling net income despite rising revenues.
Gross margin28.56%
Net profit margin2.26%
Operating margin5.95%
Return on assets1.06%
Return on equity1.82%
Return on investment1.30%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Frontage Holdings Corp fell by 34.25m. However, the company earned 39.74m from its operations for a Cash Flow Margin of 15.29%. In addition the company generated 12.91m cash from financing while 87.63m was spent on investing.
Cash flow per share0.1653
Price/Cash flow per share3.67
Book value per share1.29
Tangible book value per share0.4303
More ▼

Balance sheet in USDView more

Frontage Holdings Corp has a Debt to Total Capital ratio of 31.10%, a higher figure than the previous year's 27.77%.
Current ratio1.28
Quick ratio1.25
Total debt/total equity0.4546
Total debt/total capital0.311
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -57.73%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-6.74
EPS (TTM) vs
TTM 1 year ago		-64.96
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.